Test Id : CS1CS
Contactin-Associated Protein-1 (CASPR1)-IgG, Cell Binding Assay, Serum (Non-Orderable)
Useful For
Suggests clinical disorders or settings where the test may be helpful
Only orderable as part of a profile. For more information see:
CIDP / Chronic Inflammatory Demyelinating Polyradiculoneuropathy/Nodopathy Evaluation, Serum
CNES / Peripheral Nervous System Comprehensive Neuropathy, Autoimmune Evaluation, Serum
DMNES / Peripheral Nervous System Demyelinating Neuropathy, Autoimmune Evaluation, Serum
Evaluating patients with suspected peripheral neuropathy
Method Name
A short description of the method used to perform the test
Only orderable as part of a profile. For more information see:
-CIDP / Chronic Inflammatory Demyelinating Polyradiculoneuropathy/Nodopathy Evaluation, Serum
-CNES / Peripheral Nervous System Comprehensive Neuropathy, Autoimmune Evaluation, Serum
-DMNES / Peripheral Nervous System Demyelinating Neuropathy, Autoimmune Evaluation, Serum
Cell-Binding Assay (CBA)
NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test
Aliases
Lists additional common names for a test, as an aid in searching
CIDP
Chronic inflammatory demyelinating polyneuropathy
Demyelinating neuropathy
Chronic immune sensory polyradiculopathy
CASPR1
Anti-CASPR1
CISP
CASPR1 - Contactin associated protein 1
Specimen Type
Describes the specimen type validated for testing
Serum
Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing
Only orderable as part of a profile. For more information see:
-CIDP / Chronic Inflammatory Demyelinating Polyradiculoneuropathy/Nodopathy Evaluation, Serum
-CNES / Peripheral Nervous System Comprehensive Neuropathy, Autoimmune Evaluation, Serum
-DMNES / Peripheral Nervous System Demyelinating Neuropathy, Autoimmune Evaluation, Serum
Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the testing laboratory. The minimum volume is sufficient for one attempt at testing.
Serum: 0.5 mL
Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
| Gross icterus | Reject |
Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Refrigerated (preferred) | 28 days | |
| Ambient | 72 hours | ||
| Frozen | 28 days |
Useful For
Suggests clinical disorders or settings where the test may be helpful
Only orderable as part of a profile. For more information see:
CIDP / Chronic Inflammatory Demyelinating Polyradiculoneuropathy/Nodopathy Evaluation, Serum
CNES / Peripheral Nervous System Comprehensive Neuropathy, Autoimmune Evaluation, Serum
DMNES / Peripheral Nervous System Demyelinating Neuropathy, Autoimmune Evaluation, Serum
Evaluating patients with suspected peripheral neuropathy
Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Contactin-associated protein-1 (CASPR1) antibody is useful in the identification of autoimmune nodopathy cases, which can resemble chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Detecting this antibody helps in selecting appropriate treatment. Patients who are CASPR1 IgG positive often do not respond well to IVIG (intravenous immunoglobulin), the standard CIDP therapy, but several have responded well to rituximab therapy. CASPR1 forms a complex with contactin-1 (CNTN1), which is important for function. Autoantibodies have been identified that can target each protein (CASPR1 or CNTN1) alone, the CNTN1/CASPR1 complex, or both. Identifying the presence of these autoantibodies is useful in evaluating patients with suspected autoimmune peripheral neuropathy.
Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Only orderable as part of a profile. For more information see:
-CIDP / Chronic Inflammatory Demyelinating Polyradiculoneuropathy/Nodopathy Evaluation, Serum
-CNES / Peripheral Nervous System Comprehensive Neuropathy, Autoimmune Evaluation, Serum
-DMNES / Peripheral Nervous System Demyelinating Neuropathy, Autoimmune Evaluation, Serum
Negative
Interpretation
Provides information to assist in interpretation of the test results
Seropositivity for contactin-associated protein-1 IgG is consistent with an immune mediated demyelinating neuropathy. A paraneoplastic basis should be considered, according to age, sex, and other risk factors.
Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
A negative contactin-associated protein-1 IgG result doesn’t exclude an immune mediated demyelinating neuropathy.
Clinical Reference
Recommendations for in-depth reading of a clinical nature
1. Paramasivan NK, Basal E, LaFrance-Corey RG, et al. Clinical insights into CASPR1 and CASPR1/contactin-1 complex autoimmune nodopathies. Neurology. 2026;106(5):e214403. doi:10.1212/WNL.0000000000214403
2. Pascual-Goni E, Fehmi J, Lleixa C, et al. Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy. Brain. 2021;144(4):1183-1196. doi:10.1093/brain/awab014
3. Doppler K, Appeltshauser L, Villmann C, et al. Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy. Brain. 2016;139(Pt 10):2617-2630. doi:10.1093/brain/aww189
4. Bresciani L, Salvalaggio A, Vegezzi E, et al. Caspr1 antibodies autoimmune paranodopathy with severe tetraparesis: Potential relevance of antibody titers in monitoring treatment response. J Peripher Nerv Syst. 2023;28(3):522-527. doi:10.1111/jns.12565
Method Description
Describes how the test is performed and provides a method-specific reference
Patient sample is applied to a composite slide containing transfected and nontransfected EU90 cells. After incubation and washing, fluorescein-conjugated goat-antihuman IgG is applied to detect the presence of patient IgG binding.(Package insert: IIFT: Neurology Mosaics, Instructions for the indirect immunofluorescence test. EUROIMMUN; FA_112d-1_A_UK_C13, 02/25/2019)
PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information
Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.
Monday through Sunday
Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.
Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location
Indicates the location of the laboratory that performs the test
Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact Customer Service.
Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
CPT codes are provided by the performing laboratory.
CPT codes are provided by the performing laboratory.
86255 x2
LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.
| Test Id | Test Order Name | Order LOINC Value |
|---|---|---|
| CS1CS | CASPR1-IgG CBA, S | No LOINC Needed |
| Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
|---|---|---|
| 623393 | CASPR1-IgG CBA, S | 101448-9 |
| 624189 | CASPR1/Contactin-1 Complex | In Process |